Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
31,523,534
-
Total 13F shares
-
1,292,326
-
Share change
-
+54,256
-
Total reported value
-
$6,949,376
-
Put/Call ratio
-
48%
-
Price per share
-
$5.36
-
Number of holders
-
19
-
Value change
-
+$205,270
-
Number of buys
-
6
-
Number of sells
-
12
Institutional Holders of ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) as of Q4 2021
As of 31 Dec 2021 ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) had 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 1,292,326 shares of stock of the company.
Largest 10 holders included INGALLS & SNYDER LLC, BANK OF MONTREAL /CAN/, MARSHALL WACE, LLP, Ikarian Capital, LLC, CREDIT SUISSE AG/, CITADEL ADVISORS LLC, Federation des caisses Desjardins du Quebec, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Gradient Capital Advisors, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This table shows 20 institutional shareholders of the security as of 31 Dec 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.